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Summary The activation and proliferation of peripheral blood mononuclear cells (PBMNCs) are complex
processes involving several surface molecules, cell secretion and response to cytokines. This paper investigates
the immunomodulatory effect of prophylactic treatment with interferon alpha 2b (IFN-2b) upon the blasto-
genic response of PBMNCs from patients with superficial transitional cell carcinoma (STCC) of the bladder to
mitogenic signals that interact with surface molecules [phytohaemagglutinin, PHA and anti-CD3 monoclonal
antibodies, (MAbs)]. PBMNCs from the patients were studied prior to the transurethral resection (TUR) of
the tumour, during the second month of prophylactic intravesical instillation of IFN-M2b and 3 and 6 months
after finishing the instillation treatment. The ['H]thymidine uptake of PBMNCs from 17 patients with STCC
of the bladder after 5 days of PHA and anti-CD3 MAb stimulus was found to be significantly lower than that
of healthy controls (P<0.05). The addition of interleukin 2 (IL-2) to the culture medium did not correct this
defective proliferative response to PHA and the anti-CD3 MAb. There were no significant differences between
IL-2 production in PBMNCs from STCC patients after stimulation with PHA and in PBMNCs from healthy
controls (P>0.05). Patients without evidence of recurrence showed a significantly enhanced proliferative
response in PBMNC to PHA and anti-CD3 MAb after intravesical prophylactic treatment with interferon-M2b
in the follow-up examinations 3 and 6 months after treatment (P<0.01). However, three patients had evidence
of tumour recurrence, and they showed no enhancement of the PBMNC proliferative response to these
mitogens in the same examinations. In conclusion, the prophylactic intracavitary treatment of STCC with
IFN-M2b may induce a systemic immunomodulatory effect which is associated to the clinical evolution of the
disease.
Superficial transitional cell carcinoma (STCC) of the bladder
is the most frequent presentation of bladder tumours
(Silverberg & Lubere, 1988; Raghavan et al., 1990). These
tumours have a high tendency to recur either at the same
stage and grade or as deeply invasive tumours after the initial
endoscopic surgical resection (Torti & Lum, 1987; Raghavan
et al., 1990; Lynch et al., 1991). This evolution by STCC of
the bladder poses a common problem in its treatment and
points to the need for effective prophylactic treatment.
Adjuvant intravesical instillation of cytotoxic chemotherapy
or immunomodulators have been employed to this end for
the last few years (Raghavan et al., 1990; Witjes & Debruyne,
1991; Lamm et al., 1992). Different immunomodulators, such
as Calmette-Guerin bacillus (BCG), keyhole limpet haemo-
cyanin (KLH) and interferon alpha (IFN-a), have been used
as prophylactic treatments ofthese tumours with encouraging
clinical results (Morales et al., 1976; Jurincic et al., 1988;
Glashan, 1990) even though their mechanisms of action are
still not well understood.
It has been claimed that the immune system plays an
important role in the host's defence mechanisms against the
local growth and systemic dissemination of tumour cells
(Old, 1981; Urban et al., 1982; Alvarez-Mon et al., 1986).
Several cellular and molecular components of the immune
system are involved in the production of an efficient immune
response against these tumour cells (Grimm et al., 1982;
Alvarez-Mon et al., 1986; Hiserodt & Chambers, 1988). T
lymphocytes have a pivotal role in the regulation of this
immune response (Melief & Kast, 1991; van der Bruggen &
Van der Eynde, 1992). Their activation and proliferation are
complex processes which involve several surface molecules,
intracytoplasmic enzymatic systems and cytokines (Kehrl et
al., 1986; Crabtree, 1989; Mizoguchi et al., 1992). The
activating effect of this interaction can be simulated in vitro
by the interaction of different polyclonal mitogens, such as
vegetable lectins and anti-CD3 MAb, with the T-lymphocyte
surface molecules (Valentine et al., 1985; Davis et al., 1986).
T-lymphocyte activation is associated with the IL-2 pathway
that regulates T-cell proliferation (Ruscetti, 1990).
The progression of T lymphocytes through the cell cycle
phases is associated with the activation of genes regulating
the synthesis of both the IL-2 receptor chains and the IL-2
molecule. Secretion of IL-2 and its interaction with the
specific T-cell surface receptors provokes the progression of
the T lymphocytes through the final phases of the cell cycle
and regulates subsequent proliferation (Ruscetti, 1990).
The existence of functional alterations in T lymphocytes
and NK cells has been reported previously in patients with
TCC of the bladder. The intensity of this impairment of
peripheral blood T lymphocytes and NK cells appears to be
related to the progression of the disease (Bubenick et al.,
1988; Carballido et al., 1990; Richner et al., 1991).
This paper has investigated the function of PBMNCs from
patients with STCC of the bladder before, during and after
prophylactic treatment with intravesical instillation of IFN-
(2b*
Materials and methods
Patients and treatments
Seventeen patients with histologically proven transitional cell
bladder carcinoma were studied. The extent of tumour
invasion was classified according to the tumour, nodes and
metastasis staging system adopted by the International
Union Against Cancer. All the tumours in the study were
superficial (stages TA and TI and grades 1-3); they were
routinely completely resected with the muscle layer in each
case and randomised multiple biopsies were taken. None of
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the patients had received any treatment within the last 6
months prior to the study. Forty-eight age- and sex-matched
healthy controls were selected for the study. Of the 17 his-
tologically proven transitional cell carcinomas analysed, five
were stage pTA and 12 were stage pT1; nine were grade II
and eight grade III (Table I). Five of the 17 tumours were
recurrences of a previous STCC of the bladder; the other 12
patients had no previous history of the disease. All the
patients were studied prior to transurethral resection (TUR)
of the tumour, during the second of 3 months of treatment
with weekly intracavitary instillation of 50 x 106 IU of IFN-
a2b (intron A) and at 3 and 6 months after treatment. One
year after finishing the prophylactic IFN-M2b intravesical
treatment, none of the five patients who were being treated
for a recurrence of an earlier STCC had had a new recur-
rence and nine of the patients who had no previous history
of the disease had not had a recurrence. However, three
patients who had had no previous history of the disease did
have a recurrence during this time. Blood samples were
obtained before the surgical and anaesthetic procedures and
informed patient consent for the study was secured.
Reagents
Human recombinant IL-2 was obtained from Eurocetus
(Amsterdam, The Netherlands).
Cell separation
PBMNCs were obtained by density-gradient centrifugation
(Ficoll-Hypaque) (Lymphoprep, Nyegaard, Oslo, Norway)
and suspended in RPMI-1640 (Whitaker Bioproducts,
Walkersville, MD, USA) containing 10% heat-inactivated
fetal bovine serum (Biochrom, Berlin, Germany), L-glutamine
(2 mM Flow Lab., Irvine, UK), Hepes (0.5%, Flow Lab.)
and 1% penicillin-streptomycin (Difco Lab., Detroit, MI,
USA), This will be referred to as complete medium. Next,
cell viability was checked by trypan blue exclusion. After
counting cells were resuspended in complete medium.
Proliferation studies
PBMNCs (1 x 106 ml1) were cultured in complete medium
on 96 flat-bottomed cultured plates with one of the follow-
ing: phytohaemagglutinin (PHA, 10jgml', Difco Lab.) and
plastic-immobilised anti-CD3 MAb (5 igml1', Ortho Diag-
nostics, Raritan, NJ, USA) either alone or in the presence of
IL-2 (100 IU ml-'). These reagents were tested in
dose-response titrations before use. Cultures were incubated
at 37°C in a humid atmosphere containing 5% carbon diox-
ide for 3, 5 and 7 days. Twenty-four hours before the end of
incubation, DNA synthesis was measured by incorporation
of [3H]thymidine (1 PiCi, ICN Radiochemicals, Irvine, CA,
USA). Then, cells were harvested and the results expressed as
mean counts per minute (c.p.m.) of triplicate cultures ± esti-
mated error.
Table I Patient and tumour characteristics
No. of patients 17
No. of men/no. of women 17:0
Mean age ± s.e. at diagnosis 66.2 ± 4.3
Primary tumour/recurrent tumour 12:5
Solitary tumour/multiple tumour 11:6
Associated tumour in situ 0
Histological grade
1 0
2 9
3 8
Histological stage
pTA 5
pTl 12
Measurement ofIL-2production
IL-2-enriched supernatants were obtained by culturing
PBMNCs from healthy controls and patients with STCC of
the bladder at a density of 5 x 106cellsml1 in complete
medium in the presence of PHA (10 igml'). Supernatants
were harvested at 24 h of incubation, sterilised by filtration
through an 0.22tLm filter (Millipore Company, Bedford, CA,
USA) and stored at - 40°C until use. Concentrations of IL-2
were determined in the supernatants by enzymoimmunoassay
(Genzyme Corporation, Cambridge, MA, USA) and results
expressed in pgml-'.
Staining ofcells andflow cytometry analysis
For immunofluorescence staining, PBMNCs were incubated
with combinations of fluorescein- (FITC, green) and
phycoerythrin (PE, red)-labelled MAbs. Control studies
involving unstained cells and cells incubated with isotype-
matched irrelevant FITC- and PE-labelled MAbs were per-
formed with each experiment. The following two-colour
MAbs were used to identify PBMNC populations: Simultest
LeucoGATE (CD45 + CD14) (FITC + PE), Simultest con-
trol (IgG, + IgGu) (FITC + PE), Simultest anti-leu-4
(FITC) + anti-leu-3 (PE) (CD3 + CD4), anti-leu-2a (PE)
(CD8) and anti-leu-4 (FITC) (CD3). All MAbs were
obtained from Beckton-Dickinson (Mountain View, CA,
USA). Acquisition and analysis for two-colour
immunofluorescence procedures were carried out with a
FACScan flow cytometer using Lysis II software, as
previously described (Garcia-Suairez et al., 1993).
Statistical analysis
To analyse the results, data from the groups were compared
with the unpaired Mann-Whitney U-test. For paired com-
parisons of the data from the same group, determinations
were made using the Wilcoxon matched-pairs sign test. A
P-value of less than 0.05 was considered to indicate a
significant difference between groups.
Results
We began our study with the analysis of the proliferative
response of PBMNCs from patients with STCC of the blad-
der to stimulation with the vegetable lectin PHA. As can be
seen in Figure 1, PBMNCs from study patients show a
significantly decreased blastogenic response to PHA with
respect to that found in PBMNCs from healthy controls after
5 days of culture (P<0.05). There were no significant
differences between the proliferative response of PBMNCs
from STCC patients and healthy controls to PHA stimula-
tion at days 3 and 7 of culture (P>0.05). There was no
relevant proliferation of PHA-stimulated PBMNCs from
either STCC patients or healthy controls after 9 days of
culture (data not shown).
Since the PHA lectin interacts with multiple surface
molecules, we investigated the proliferative response of
PBMNCs from STCC patients to mitogens that selectively
recognise the monomorphic CD3 structures associated with
the clonotypic T-cell receptor. As shown in Figure 2, the
[3H]thymidine uptake found in the PBMNC cultures from
STCC patients in the presence of MAbs against CD3 was
significantly lower than that found in PBMNCs from healthy
controls after 5 days of culture (P<0.05). There were no
significant differences between the proliferative response of
PBMNCs from STCC patients and healthy controls to anti-
CD3 MAb stimulation at days 3 and 7 of culture (P>0.05).
This defective proliferative response of PBMNCs to poly-
clonal mitogens from patients can not be associated with a
diminished CD3+ T-lymphocyte percentages or with a redis-
tribution of the CD3+4+ and CD3+8+ T-lymphocyte subsets,
since there were no significant differences between the per-
centages ofcells stained with the different MAbs in PBMNCsT-CELL ACTIVATION IN IFN-a 2b-TREATED PATIENTS WITH STCC OF THE BLADDER 1249
from STCC patients and healthy controls after culturing with
PHA for 24 h. As shown in Figure 4, there were no
significant differences between the IL-2 concentration in the
supernatants of the PBMNCs from STCC patients and that
in the supernatants of PBMNCs from healthy controls
(P>0.05).
Normalisation oftheproliferative response to mitogens of
PBMNCfrom STCCpatients after intravesical instillations
with IFN-c2b
Next, we studied the proliferative response to PHA and
anti-CD3 MAb in PBMNCs from intracavitarily treated
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Figure 1 PBMNCs from patients with STCC of the bladder
(n = 17) (0) show a significantly decreased blastogenic response
to PHA with respect to that found in PBMNCs from healthy
controls (n = 48) (Ol) after 5 days of culture (P<0.05). Results
represent the mean plus the standard deviation (s.d.) of the
triplicate proliferation assays from each group of subjects after 3,
5 and 7 days of culture.
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Figure 3 IL-2 ( ) did not significantly enhance the pro-
liferative response of PBMNCs to PHA and anti-CD3 MAb
(P>0.05) from patients with STCC of the bladder (n = 17).
Results represent the median and the range values of the different
triplicate proliferation assays from the same group of subjects
after 5 days of culture.
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Figure 2 The proliferative response of PBMNCs from patients
with STCC of the bladder (n = 17) (0) to stimulation with
anti-CD3 MAb was significantly lower than that found in
PBMNCs from healthy controls (n = 48) (0) after 5 days of
culture (P<0.05). Results are expressed as the mean ± s.d. of the
triplicate proliferation assays from each group of subjects after 3,
5 and 7 days of culture.
from STCC patients (CD3+, 73 ± 5%; CD3+CD4+,
43 ± 3%; CD3+CD8+, 32 ± 4%) or from the healthy con-
trols (CD3+, 75 ± 4%; CD3+CD4+, 45 ± 4%; CD3+CD8+,
31 ± 4%).
Since IL-2 plays a pivotal role in T-lymphocyte blasto-
genesis, we investigated the effect of IL-2 upon the
diminished proliferative response to PHA and anti-CD3
MAb stimulation in PBMNCs from patients with STCC of
the bladder. As can be seen in Figure 3, the exogenous
addition of saturated amounts of IL-2 to the PBMNC cul-
tures from STCC patients did not significantly enhance the
diminished proliferative response of PBMNC to PHA and
anti-CD3 MAb after 5 days of culture (P>0.05).
We also investigated the IL-2 production by PBMNCs
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Figure 4 The IL-2 production by PBMNCs in PHA-stimulated
cultures from patients with STCC of the bladder (n = 11) ( = )
was not significantly different from that found in the super-
natants of PBMNCs from healthy controls (n = 10) ( 1 ) after
24 h of culture (P> 0.05). Results represent the median and the
range values of duplicate samples performed in a solid-phase
Intertest-2 human ELISA kit and expressed as pgml-'.
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STCC patients with or without evidence of tumour recur-
rence after 1 year of follow-up. We found that the pro-
liferative response of PBMNCs from STCC patients without
evidence of recurrence to these mitogens increased during the
first 6 weeks of treatment without there being any significant
difference with respect to the same patient's proliferative
response before the intracavitary treatment (P>0.05). How-
ever, at 3 and 6 months after the treatment, the blastogenic
response to the mitogens in the PBMNCs from these patients
was significantly higher than that found before initiating the
treatment (P<0.01). The post-treatment proliferative re-
sponse by PBMNCs from STCC patients was similar to that
found in healthy controls (P<0.05) (Figure 5). In contrast,
in the three patients with evidence of tumour recurrence
during the 12 months of follow-up, we did not find a signifi-
cant enhancement of the proliferative response of PBMNCs
to the PHA or anti-CD3 MAb after the treatment (Figure 6).
Six healthy controls who were studied at the same times as
the STCC patients showed no significant modifications in the
proliferative response of PBMNCs to these mitogens
(P>0.05) (median values of initial proliferative response to
PHA, 78,999 c.p.m. with a range of 28,311-116,973 c.p.m.;
at 3 months of follow-up, 94,232 c.p.m. with a range of
28,262-208,589 c.p.m.; and at 6 months of follow-up
83,583 c.p.m. with a range of 33,398-202,171.
Discussion
This paper demonstrates that the prophylactic intracavitary
use of IFN--2b in patients with STCC of the bladder after
TUR is associated with a systemic immunomodulator
effect.
TCC of the bladder is known to be associated with
different immune system alterations (Bubenick et al., 1988;
Carballido et al., 1990; Richner et al., 1991). These T- and
NK-function impairments appear to be related to the pro-
gression of the disease. In patients with STCC of the bladder
we have found that the proliferative response of PBMNCs to
T-lymphocyte polyclonal mitogens is reduced. This defective
mitogenic response in patients with STCC cannot be returned
to normal by the exogenous addition of IL-2 to the culture
medium. Furthermore, the IL-2 production after PHA
stimulation in PBMNCs from patients with STCC is not
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Figure 5 The proliferative response to PHA ( =O) and anti-
CD3 MAb ( m ) of PBMNCs from STCC patients treated with
intracavitary IFN-ac2b without evidence of tumour recurrence
(n = 14) was significantly higher 3 and 6 months after finishing
the treatment than that found before initiating it (P<0.01).
Results are expressed as the median and the range values of the
different triplicate proliferation assays from the same group of
subjects after 5 days of culture.
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Figure 6 There was no significant enhancement of the pro-
liferative response of PBMNCs to (a) PHA and (b) anti-CD3 in
patients with STCC of the bladder with evidence of tumour
recurrence at 3 and 6 months after treatment with intravesical
IFN-a2b instillations. Results represent the mean individual values
of the triplicate proliferation assays from each patient (n = 3)
after 5 days of culture.
significantly decreased with respect to that found in healthy
controls. A similar pattern of abnormal function of the T-cell
compartment of peripheral blood has been found in patients
with other tumours or with autoimmune diseases (Braun et
al., 1983; Mantovani et al., 1987; Gaspar et al., 1988).
We have clearly demonstrated that there is a significant
enhancement of the proliferative response of PBMNCs to
polyclonal mitogens in the STCC patients who were treated
prophylactically with intravesical instillations of IFN-a2b and
who remained free of tumour recurrence after 1 year of
follow-up. This immunomodulator effect by the intravesical
instillation of IFN-a2b in STCC patients does not appear to
be a consequence of any direct effect of this cytokine upon
PBMNCs. It has been shown that intravesical instillation of
IFN-a is associated with an immune infiltration of the blad-
der wall (P. Ferrari, personal communication). Thus, this
systemic effect of intravesical IFN-a2b could be explained by
a local bladder wall immune activation with systemic func-
tional consequences. It has been shown previously that the
different cellular components of the immune system have
multiple functional interactions as well as different distribu-
tions throughout the body (Goodman & LeFrangois, 1989:
Picker et al., 1990). Interestingly, the patients whose
PBMNCs did not show an enhanced proliferative response to
polyclonal mitogens after intravesical IFN-a2b instillations
were the ones whose disease recurred. This finding could be
related to a different pattern of immune infiltrations on the
bladder wall and/or to an abnormal immune system in this
particular group of patients. Studies performed with intra-
cavitary instillations of other immunomodulators such as
BCG in the prophylactic treatment of patients with TCC
have shown that the immunomodulators are associated with
an increase in bladder wall infiltration by some cells and with
a local production of cytokines (Peumchair et al., 1989;
Bohle et al., 1990a,b).
IFN-a2b also directly inhibits tumour cell proliferation
(Fish et al., 1983). Thus, this antiproliferative effect could
also be involved in the mechanism of action of IFN-a2b when
given by intravesical instillations in the prophylactic treat-
ment of patients with STCC of the bladder. However, IFN-
a2b also has an in vitro immunomodulator effect upon the
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cytotoxic immune effector cells (Carballido et al., 1993). The
present paper has demonstrated that intracavitary instillation
of IFN-M2b in patients with STCC of the bladder is also
associated with an in vivo immunomodulator effect. Thus, it
can be claimed that the immunomodulator effect of IFN-x is
also implicated in the mechanism of action of this cytokine in
the prophylaxis of tumour recurrences in patients with
STCC. Further studies are needed to define the cellular and
molecular mechanisms involved in this immunomodulator
effect by intravesical IFN-22b instillations and their results
might serve as clinical prognostic parameters for patients
suffering from these malignancies.
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